Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | FDPS | P14324 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9011883 | 1.00 | TP53 (0.50) | TP53GPR84FDPSFFAR1LMNA | |
| SCHEMBL3426182 | 1.00 | TP53 (0.50) | TP53GPR84FDPSFFAR1LMNA | |
| SCHEMBL28382455 | 1.00 | TP53 (0.50) | TP53GPR84FDPSFFAR1LMNA | |
| SCHEMBL7134938 | 1.00 | TP53 (0.50) | TP53GPR84FDPSFFAR1LMNA | |
| SCHEMBL9660948 | 0.98 | TP53 (0.48) | TP53GPR84FDPSFFAR1LMNA | |
| SCHEMBL8609916 | 0.98 | TP53 (0.48) | TP53GPR84FDPSFFAR1LMNA | |
| SCHEMBL8813654 | 0.98 | TP53 (0.52) | TP53GPR84FDPSFFAR1LMNA | |
| SCHEMBL28084442 | 0.96 | TP53 (0.47) | TP53GPR84FDPSFFAR1LMNA | |
| SCHEMBL9460109 | 0.96 | TP53 (0.54) | TP53GPR84FDPSFFAR1LMNA | |
| SCHEMBL6128322 | 0.96 | TP53 (0.54) | TP53GPR84FDPSFFAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110016284-B | Conductive polymer composition, cover and pattern forming method | 信越化学工业株式会社 | 2023-08-08 | — | — | CN | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
| US-8657966-B2 | Combinatorial approach to the development of cleaning formulations for glue removal in semiconductor applications | INTERMOLECULAR, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20110146727-A1 | COMBINATORIAL APPROACH TO THE DEVELOPMENT OF CLEANING FORMULATIONS FOR GLUE REMOVAL IN SEMICONDUCTOR APPLICATIONS | INTERMOLECULAR, INC. | 2011-06-23 | — | — | US | disclosed |
| WO-2010019722-A2 | COMBINATORIAL APPROACH TO THE DEVELOPMENT OF CLEANING FORMULATIONS FOR GLUE REMOVAL IN SEMICONDUCTOR APPLICATIONS | INTERMOLECULAR, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-1051393-B1 | NEW DERIVATIVES OF SULFONIC, PHOSPHONIC AND PHOSPHINIC AMINOALKANE ACIDS, THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | MERCK SANTE SAS (FR) | 2003-10-01 | — | — | EP | disclosed |
| EP-1051393-A1 | NEW DERIVATIVES OF SULFONIC, PHOSPHONIC AND PHOSPHINIC AMINOALKANE ACIDS, THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | LIPHA (FR) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037606-A1 | NEW DERIVATIVES OF SULFONIC, PHOSPHONIC AND PHOSPHINIC AMINOALKANE ACIDS, THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | LIPHA (FR) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | TP53 2836/4885GPR84 133/4885FDPS 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.